The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer’s disease

Histochemistry and Cell Biology

Volumn 144, Issue 4, 2015, Pages 293-308

  Brock, Amanda J ^a   Kasus Jacobi, Anne ^a   Lerner, Megan ^b   Logan, Sreemathi ^a   Adesina, Adekunle M ^c   Anne Pereira, H ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Amyloid beta; CAP37; Microglia; Neuroinflammation; Neurons

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AZU1 PROTEIN; CAP37 PROTEIN; ELANE PROTEIN; ELASTASE; MYELOBLASTIN; PROTEIN; PRTN3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; CARRIER PROTEIN; CATIONIC ANTIMICROBIAL PROTEIN CAP 37, HUMAN; PEPTIDE FRAGMENT; PLASMA PROTEIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN CELL; BRAIN TISSUE; CONTROLLED STUDY; DENTATE HILUS; ENDOTHELIUM CELL; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROGLIA; NEUTROPHIL; PARIETAL LOBE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TEMPORAL LOBE; UPREGULATION; WESTERN BLOTTING; ADULT; AGED; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELLS, CULTURED; HUMANS; INFLAMMATION MEDIATORS; MALE; PARIETAL LOBE; PEPTIDE FRAGMENTS; PRIMARY CELL CULTURE; PYRAMIDAL CELLS; TEMPORAL LOBE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84942342580     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-015-1347-x     Document Type: Article

References (56)

1. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gerard HC, Hudson AP (2008) Chlamydophila pneumoniae and the etiology of late-onset Alzheimer’s disease. J Alzheimers Dis 13(4):371–380
2. Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, Yi X, Deng B, Liu CH, Xu J, Zhang LL, Gao CY, Xu ZQ, Zhang M, Wang L, Tan XL, Xu X, Zhou HD Wang YJ (2014) A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. doi:10.1111/ene.12477
3. Citron M (2004) Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci 5(9):677–685
4. Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9(5):387–398
5. Davies BJ, Pickard BS, Steel M, Morris RGM, Lathe R (1998) Serine proteases in rodent hippocampus. J Biol Chem 273(36):23004–23011
6. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90(2):465–494
7. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA (2006) Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 20(3):426–433
8. Doens D, Fernandez PL (2014) Microglia receptors and their implications in the response to amyloid beta for Alzheimer’s disease pathogenesis. J Neuroinflammation 11:48
9. Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA (2012) Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer’s disease. Alzheimers Res Ther 4(3):15
10. Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab 33(10):1500–1513
11. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain 119(Pt 6):2001–2007
12. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L (2001) Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 7(10):1123–1127
13. Gonzalez ML, Ruan X, Kumar P, Grammas P, Pereira HA (2004) Functional modulation of smooth muscle cells by the inflammatory mediator CAP37. Microvasc Res 67(2):168–181
14. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer’s disease. J Neuroinflammation 8:26
15. Griffith GL, Russell RA, Kasus-Jacobi A, Thavathiru E, Gonzalez ML, Logan S, Pereira HA (2013) CAP37 activation of PKC promotes human corneal epithelial cell chemotaxis. Invest Ophthalmol Vis Sci 54(10):6712–6723
16. Griffith GL, Kasus-Jacobi A, Lerner MR, Pereira HA (2014) Corneal wound healing, a newly identified function of CAP37, is mediated by protein kinase C delta (PKCdelta). Invest Ophthalmol Vis Sci 55(8):4886–4895
17. Harrington CR (2012) The molecular pathology of Alzheimer’s disease. Neuroimaging Clin N Am 22(1):11–22
18. Heneka MT, O’Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm 117(8):919–947
19. Hensley K (2010) Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 21(1):1–14
20. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I (2013) Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol 260(11):2722–2727
21. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K (2013) The diagnostic value of CSF alpha- synuclein in the differential diagnosis of dementia with Lewy bodies versus normal subjects and patients with Alzheimer’s disease. PLoS One 8(11):e81654
22. Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, Small SA (2014) Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease. Nat Neurosci 17(2):304–311
23. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F (2010) Neutrophil elastase, proteinase 3 and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 62(4):726–759
24. Lee TD, Gonzalez ML, Kumar P, Chary-Reddy S, Grammas P, Pereira HA (2002) CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions. Am J Pathol 160(3):841–848
25. Ley K (2001) Plugging the leaks. Nat Med 7(10):1105–1106
26. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P (2009) Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis 49(7):1044–1050
27. Linder A, Akesson P, Brink M, Studahl M, Bjorck L, Christensson B (2011) Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. Crit Care Med 39(4):812–817
28. Marques F, Sousa JC, Sousa N, Palha JA (2013) Blood-brain-barriers in aging and in Alzheimer’s disease. Mol Neurodegener 8:38
29. McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126(4):479–497
30. Miklossy J (2008) Chronic inflammation and amyloidogenesis in Alzheimer’s disease—role of Spirochetes. J Alzheimers Dis 13(4):381–391
31. Nakajima K, Shimojo M, Hamanoue M, Ishiura S, Sugita H, Kohsaka S (1992) Identification of elastase as a secretory protease from cultured rat microglia. J Neurochem 58(4):1401–1408
32. Pereira HA (1995) CAP37, a neutrophil-derived multifunctional inflammatory mediator. J Leukoc Biol 57(6):805–812
33. Pereira HA (2006) Novel therapies based on cationic antimicrobial peptides. Curr Pharm Biotechnol 7(4):229–234
34. Pereira HA, Shafer WM, Pohl J, Martin LE, Spitznagel JK (1990a) CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. J Clin Invest 85(5):1468–1476
35. Pereira HA, Spitznagel JK, Pohl J, Wilson DE, Morgan J, Palings I, Larrick JW (1990b) CAP 37, a 37 kD human neutrophil granule cationic protein shares homology with inflammatory proteinases. Life Sci 46(3):189–196
36. Pereira HA, Erdem I, Pohl J, Spitznagel JK (1993) Synthetic bactericidal peptide based on CAP37: a 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proc Natl Acad Sci USA 90(10):4733–4737
37. Pereira HA, Kumar P, Grammas P (1996a) Expression of CAP37, a novel inflammatory mediator, in Alzheimer’s disease. Neurobiol Aging 17(5):753–759
38. Pereira HA, Moore P, Grammas P (1996b) CAP37, a neutrophil granule-derived protein stimulates protein kinase C activity in endothelial cells. J Leukoc Biol 60(3):415–422
39. Pereira HA, Ruan X, Kumar P (2003) Activation of microglia: a neuroinflammatory role for CAP37. Glia 41(1):64–72
40. Pereira HA, Ruan X, Gonzalez ML, Tsyshevskaya-Hoover I, Chodosh J (2004) Modulation of corneal epithelial cell functions by the neutrophil-derived inflammatory mediator CAP37. Invest Ophthalmol Vis Sci 45(12):4284–4292
41. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6(4):193–201
42. Piacentini R, De Chiara G, Li Puma DD, Ripoli C, Marcocci ME, Garaci E, Palamara AT, Grassi C (2014) HSV-1 and Alzheimer’s disease: more than a hypothesis. Front Pharmacol 5:97
43. Ruan X, Chodosh J, Callegan MC, Booth MC, Lee TD, Kumar P, Gilmore MS, Pereira HA (2002) Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci 43(5):1414–1421
44. Saido T, Leissring MA (2012) Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med 2(6):a006379
45. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC (2002) Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 99(7):4703–4707
46. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J Jr, Boxer AL (2014) Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 75(1):116–126
47. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189
48. Skondra D, Noda K, Almulki L, Tayyari F, Frimmel S, Nakazawa T, Kim IK, Zandi S, Thomas KL, Miller JW, Gragoudas ES, Hafezi-Moghadam A (2008) Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown. Invest Ophthalmol Vis Sci 49(2):726–731
49. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5(3):e9505
50. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S (2003) Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 16(3):136–144
51. Urosevic N, Martins RN (2008) Infection and Alzheimer’s disease: the APOE epsilon4 connection and lipid metabolism. J Alzheimers Dis 13(4):421–435
52. van Sorge NM, Doran KS (2012) Defense at the border: the blood-brain barrier versus bacterial foreigners. Future Microbiol 7(3):383–394
53. Welling MM, Nabuurs RJ, van der Weerd L (2015) Potential role of antimicrobial peptides in the early onset of Alzheimer’s disease. Alzheimers Dement 11(1):51–57
54. White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, Hartshorn KL (2014) Alzheimer’s associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One 9(7):e101364
55. Williams WM, Torres S, Siedlak SL, Castellani RJ, Perry G, Smith MA, Zhu X (2013) Antimicrobial peptide beta-defensin-1 expression is upregulated in Alzheimer’s brain. J Neuroinflammation 10:127
56. Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50(12):2041–2056